Skye Bioscience Inc
NASDAQ:SKYE
Skye Bioscience Inc
NASDAQ:SKYE
Price:
0.72
USD
-0.8%
Market Closed
Market Cap:
$24m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Skye Bioscience Inc
NASDAQ:SKYE
|
US |
|
K
|
Kleannara Co Ltd
KRX:004540
|
KR |
|
Hannover Rueck SE
XETRA:HNR1
|
DE |
|
F
|
Flexion Mobile PLC
STO:FLEXM
|
UK |
|
Bentley Systems Inc
NASDAQ:BSY
|
US |
|
M
|
Memiontec Holdings Ltd
SGX:TWL
|
SG |
|
Q
|
QTC Energy PCL
SET:QTC
|
TH |
|
Ortel Communications Ltd
NSE:ORTEL
|
IN |
|
B
|
Bank CIMB Niaga Tbk PT
IDX:BNGA
|
ID |
|
Wicaksana Overseas International Tbk PT
IDX:WICO
|
ID |
|
Marathon Oil Corp
NYSE:MRO
|
US |
|
S
|
Swadeshi Polytex Ltd
BSE:503816
|
IN |
Balance Sheet
Balance Sheet Decomposition
Skye Bioscience Inc
Skye Bioscience Inc
Balance Sheet Decomposition is not available for
Skye Bioscience Inc
Skye Bioscience Inc
Balance Sheet
Skye Bioscience Inc
Skye Bioscience Inc
Currency: USD
| Oct-2011 | Oct-2012 | Oct-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
0
|
0
|
2
|
2
|
2
|
9
|
1
|
1
|
70
|
7
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
1
|
0
|
2
|
1
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
1
|
68
|
6
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
8
|
10
|
0
|
1
|
|
| Total Current Assets |
0
|
0
|
0
|
0
|
3
|
0
|
1
|
2
|
2
|
3
|
10
|
9
|
12
|
71
|
27
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
+33%
|
0
+275%
|
0
+133%
|
4
+903%
|
0
-91%
|
1
+75%
|
2
+250%
|
2
+2%
|
3
+34%
|
10
+269%
|
9
-8%
|
12
+31%
|
73
+509%
|
28
-61%
|
|
| Liabilities | ||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
2
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
1
|
0
|
0
|
6
|
6
|
2
|
2
|
|
| Total Current Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
16
|
1
|
1
|
4
|
12
|
14
|
4
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
0
N/A
|
0
N/A
|
1
+1 233%
|
3
+280%
|
2
-42%
|
1
-23%
|
18
+1 188%
|
1
-92%
|
2
+53%
|
4
+80%
|
12
+204%
|
14
+16%
|
5
-67%
|
8
+80%
|
|
| Equity | ||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
1
|
3
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
0
|
3
|
7
|
10
|
13
|
32
|
32
|
39
|
47
|
67
|
104
|
131
|
187
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
2
|
6
|
7
|
9
|
16
|
33
|
39
|
53
|
63
|
102
|
199
|
207
|
|
| Total Equity |
0
N/A
|
0
+33%
|
0
+100%
|
0
N/A
|
0
N/A
|
1
N/A
|
1
+45%
|
16
-1 845%
|
1
N/A
|
0
-18%
|
6
+1 202%
|
3
N/A
|
2
+29%
|
68
N/A
|
20
-71%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
+33%
|
0
+275%
|
0
+133%
|
4
+903%
|
0
-91%
|
1
+75%
|
2
+250%
|
2
+2%
|
3
+34%
|
10
+269%
|
9
-8%
|
12
+31%
|
73
+509%
|
28
-61%
|
|
| Shares Outstanding | ||||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
4
|
12
|
31
|
33
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
